{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T21:15:24Z","timestamp":1778620524364,"version":"3.51.4"},"reference-count":16,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,2]],"date-time":"2025-02-02T00:00:00Z","timestamp":1738454400000},"content-version":"am","delay-in-days":398,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA045745"],"award-info":[{"award-number":["R01DA045745"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["NCT03545321"],"award-info":[{"award-number":["NCT03545321"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","japha.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Pharmacists Association"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.japh.2023.10.014","type":"journal-article","created":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T11:38:29Z","timestamp":1697629109000},"page":"71-78","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pharmacy staff-reported adaptations to naloxone provision and over-the-counter (OTC) syringe sales during the COVID-19 pandemic: Experiences across multiple states and 2 pharmacy chains"],"prefix":"10.1016","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9105-6904","authenticated-orcid":false,"given":"Traci C.","family":"Green","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2207-3457","authenticated-orcid":false,"given":"Joseph","family":"Silcox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2947-0204","authenticated-orcid":false,"given":"Derek","family":"Bolivar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5841-4095","authenticated-orcid":false,"given":"Mary","family":"Gray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1063-0132","authenticated-orcid":false,"given":"Anthony S.","family":"Floyd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2086-4493","authenticated-orcid":false,"given":"Adriane N.","family":"Irwin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3887-1242","authenticated-orcid":false,"given":"Ryan N.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0685-773X","authenticated-orcid":false,"given":"Daniel M.","family":"Hartung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2240-5768","authenticated-orcid":false,"given":"Jeffrey","family":"Bratberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.japh.2023.10.014_bib1","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1016\/j.japh.2022.07.003","article-title":"Access to community pharmacies: a nationwide geographic information systems cross-sectional analysis","volume":"62","author":"Berenbrok","year":"2022","journal-title":"J\u00a0Am Pharm Assoc"},{"issue":"13","key":"10.1016\/j.japh.2023.10.014_bib2","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2147\/SAR.S351096","article-title":"The role of the pharmacist in combating the opioid crisis: an update","volume":"Volume","author":"Kosobuski","year":"2022","journal-title":"Subst Abuse Rehabil"},{"issue":"5","key":"10.1016\/j.japh.2023.10.014_bib3","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1016\/j.japh.2022.03.014","article-title":"Using qualitative, community-based input to steer post-coronavirus disease 2019 pharmacy practice in substance use","volume":"62","author":"Kosobuski","year":"2022","journal-title":"J\u00a0Am Pharm Assoc"},{"issue":"6","key":"10.1016\/j.japh.2023.10.014_bib4","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.2105\/AJPH.2021.306228","article-title":"Expanding mail-based distribution of drug-related harm reduction supplies amid COVID-19 and beyond","volume":"111","author":"Barnett","year":"2021","journal-title":"Am J Public Health"},{"issue":"6","key":"10.1016\/j.japh.2023.10.014_bib5","doi-asserted-by":"crossref","first-page":"752","DOI":"10.15288\/jsad.2021.82.752","article-title":"Smart syringe vending machines: research capabilities and implications for research data collection","volume":"82","author":"Otiashvili","year":"2021","journal-title":"J\u00a0Stud Alcohol Drugs"},{"issue":"9","key":"10.1016\/j.japh.2023.10.014_bib6","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1007\/s10461-020-02886-2","article-title":"The impact of COVID-19 on syringe services programs in the United States","volume":"24","author":"Glick","year":"2020","journal-title":"AIDS Behav"},{"key":"10.1016\/j.japh.2023.10.014_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2020.102821","article-title":"Syringe services program (SSP) operational changes during the COVID-19 global outbreak","volume":"83","author":"Bartholomew","year":"2020","journal-title":"Int J Drug Policy"},{"key":"10.1016\/j.japh.2023.10.014_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2022.103825","article-title":"Barriers to engaging people who use drugs in harm reduction services during the COVID-19 pandemic: A mixed methods study of syringe services program perspectives","volume":"109","author":"Austin","year":"2022","journal-title":"Int J Drug Policy"},{"issue":"5","key":"10.1016\/j.japh.2023.10.014_bib9","first-page":"28","article-title":"Challenges in community pharmacy during COVID-19: the\u00a0perfect storm for personnel burnout","volume":"46","author":"Bookwalter","year":"2021","journal-title":"US Pharm"},{"issue":"3","key":"10.1016\/j.japh.2023.10.014_bib10","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.japh.2021.12.013","article-title":"Expanded roles of community pharmacists in COVID-19: A scoping literature review","volume":"62","author":"Pantasri","year":"2022","journal-title":"J\u00a0Am Pharm Assoc"},{"issue":"1","key":"10.1016\/j.japh.2023.10.014_bib11","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.japh.2022.10.012","article-title":"Examining the effects of COVID-19 on pharmacy dispensing of naloxone, buprenorphine, and syringes sales across Massachusetts and New Hampshire","volume":"63","author":"Bolivar","year":"2023","journal-title":"J\u00a0Am Pharm Assoc"},{"issue":"1","key":"10.1016\/j.japh.2023.10.014_bib12","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1080\/08897077.2021.2010162","article-title":"Study protocol for the Respond to Prevent Study: a multi-state randomized controlled trial to improve provision of naloxone, buprenorphine and nonprescription syringes in community pharmacies","volume":"43","author":"Green","year":"2022","journal-title":"Subst Abus"},{"issue":"1","key":"10.1016\/j.japh.2023.10.014_bib13","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.japh.2022.12.001","article-title":"Implementation of an academic detailing intervention to increase naloxone distribution and foster engagement in harm reduction from the community clinician","volume":"63","author":"Irwin","year":"2023","journal-title":"J\u00a0Am Pharm Assoc"},{"issue":"3","key":"10.1016\/j.japh.2023.10.014_bib14","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.japh.2023.01.013","article-title":"\u201cLike it Was Just Everyday Business\u201d: a qualitative study of Pharmacy-Based naloxone and Syringe Customer Experience","volume":"63","author":"Gray","year":"2023","journal-title":"J\u00a0Am Pharm Assoc"},{"issue":"1","key":"10.1016\/j.japh.2023.10.014_bib15","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12954-023-00739-4","article-title":"North Carolina pharmacists\u2019 willingness to sell fentanyl test strips: a survey study","volume":"20","author":"Marley","year":"2023","journal-title":"Harm Reduct J"},{"issue":"4","key":"10.1016\/j.japh.2023.10.014_bib16","first-page":"99","article-title":"Primary care wound clinics: A qualitative descriptive study of patient experiences in community pharmacies","volume":"10","author":"Sheehan","year":"2022","journal-title":"Pharmacy (Basel)"}],"container-title":["Journal of the American Pharmacists Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319123003217?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319123003217?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T20:29:47Z","timestamp":1778617787000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1544319123003217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S1544319123003217"],"URL":"https:\/\/doi.org\/10.1016\/j.japh.2023.10.014","relation":{},"ISSN":["1544-3191"],"issn-type":[{"value":"1544-3191","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacy staff-reported adaptations to naloxone provision and over-the-counter (OTC) syringe sales during the COVID-19 pandemic: Experiences across multiple states and 2 pharmacy chains","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Pharmacists Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.japh.2023.10.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc. on behalf of the American Pharmacists Association.","name":"copyright","label":"Copyright"}]}}